Europe
It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look.
Positive results from Sellas Life Sciences Group’s Phase I/II trial using galinpepimut-S (GPS) as a combination therapy with pembrolizumab (Keytruda®) were announced Wednesday, shortly after similarly positive news was issued from a combination study in which GPS was evaluated as a treatment for mesothelioma.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
NGM Biopharmaceuticals and Merck announced they had amended their existing collaboration agreement. It will continue through March 2024, but have a narrower scope.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Innate Pharma has an alternative to T cell-based immunotherapy that has the potential to quickly and safely eradicate solid and metastatic tumors in the body.
Orphazyme said that its OLE trial, which has been running for the past 24 months, showed that arimoclomol could be an effective and safe option in treating Niemann-Pick disease type C.
The trial is the third study in a set of pivotal trials to report positive data for the therapy.
She takes over the role held by oncology research legend José Baselga, who passed away in March from a neurodegenerative disease.
Polyphor said there has been no improvement in the results for FORTRESS, its Phase III global study for the possible treatment of patients with breast cancer.
PRESS RELEASES